Bio-Techne Corporation
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kim Kelderman
- Full Time Employees
- 3,100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 614 McKinley Place N.E. Minneapolis MN United States of America 55413
- IPO Date
- Feb 9, 1989
- CIK
- 0000842023
- Website
- bio-techne.com
- Similar Companies
- Business
- Bio-Techne Corporation (NASDAQ: TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and supplies high-quality reagents, analytical instruments, and precision diagnostics for biotechnology research, clinical diagnostics, bioprocessing, and cell and gene therapy applications worldwide; the company operates through two primary segments, Protein Sciences, which provides biological reagents including cytokines, antibodies, immunoassays, cell selection kits, multicolor flow cytometry kits, multiplex assays, biologically active compounds, stem cell products, and proteomic analytical tools, and Diagnostics and Genomics, which offers diagnostic products such as advanced tissue-based in-situ hybridization assays for spatial genomic analysis and tissue biopsy, exosome-based molecular diagnostic assays, controls, calibrators, genetic and oncology kits, and clinical hematology controls; key brands encompass R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, ACD, Asuragen, Lunaphore, and BiosPacific, with over 500,000 products in its catalog, 95% manufactured in-house, supporting customers in pharmaceutical, therapeutic, diagnostics, and life science industries across more than 34 global locations including subsidiaries in Europe, China, and Hong Kong. Founded in 1976 as Research and Diagnostic Systems and renamed Bio-Techne in 2014 following its 1981 incorporation, the company employs over 3,000 people and generated approximately $1.2 billion in net sales for fiscal 2024. Recent developments include a strategic distribution partnership with Spear Bio announced in July 2025 to expand access to SPEAR UltraDetect ultrasensitive immunoassays for neurology biomarkers such as pTau 231, pTau 217, GFAP, and Nf-L, following Bio-Techne's investment in Spear Bio's 2024 Series A funding; the divestiture of its Exosome Diagnostics business to Mdxhealth SA in August 2025 for $15 million plus royalties; licensing of AI-designed NovoBody Duo molecules from Monod Bio in November 2025 to enhance its recombinant protein portfolio; launch of the ProximityScope Assay on the BOND RX platform in October 2025 for spatial protein-protein interactions research; and an AI-powered spatial biology workflow collaboration with Nucleai in November 2025 for predictive biomarker discovery in melanoma patients.
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
CMB.TECH fleet update
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH)
Bio-Techne Corporation (TECH) M&A Call Transcript
Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
Germany's Merck Is Buying Bio-Techne for $11.3 Billion
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Germany's Merck to buy Bio-Techne for $73 per share
Germany's Merck to Buy Bio-Techne for $11 Billion